Class Action Lawsuit - A class action lawsuit has been filed against Orthofix Medical Inc (NASDAQ: OFIX) alleging securities fraud or other unlawful business practices by the company and certain officers/directors [1][2] - Shareholders who purchased Orthofix securities during the Class Period have until October 21, 2024 to request appointment as Lead Plaintiff [2] Executive Changes - On September 12, 2023, Orthofix announced the immediate appointment of interim CEO, CFO, and Chief Legal Officer following the termination of Keith Valentine, John Bostjancic and Patrick Keran from those roles [2] - The terminations resulted from an investigation that found the executives engaged in repeated inappropriate and offensive conduct violating the company's code of conduct and values [2] Stock Price Impact - Orthofix's stock price fell $5 62 per share or 30 17% to close at $13 01 per share on September 12, 2023 following the executive changes announcement [2] Law Firm Background - Pomerantz LLP, the law firm handling the class action, is a premier firm in corporate, securities and antitrust class litigation with offices in New York, Chicago, Los Angeles, London, Paris and Tel Aviv [3] - Founded over 85 years ago, Pomerantz has recovered billions of dollars in damages for class members in securities fraud and corporate misconduct cases [3]

Group 1 - The article reports that a class action has been filed against Orthofix Medical Inc. on behalf of shareholders who purchased stock between October 11, 2022, and September 12, 2023 [1] - The allegations state that Orthofix's management misled investors about their commitment to ethical standards and corporate values, while in reality, they engaged in inappropriate conduct [2] - Following the announcement of the termination of key executives, the company's stock price dropped by $5.62, or over 30%, closing at $13.01 per share on September 13, 2023 [2] Group 2 - Shareholders interested in participating as lead plaintiffs must submit their applications by October 21, 2024, and can remain absent class members if they choose not to participate [2] - Robbins LLP, the law firm handling the case, has a history of recovering over $1 billion for shareholders and focuses on holding company executives accountable [4]

ATLANTA, Aug. 22, 2024 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Orthofix Medical Inc. ("Orthofix" or "the Company") (NASDAQ: OFIX). The lawsuit alleges that Orthofix's management team was engaged in "repeated inappropriate and offensive conduct that violated multiple code of conduct requirements," which was "inconsistent with the Company's values and culture." When the truth about the Company's management team was revealed, the price of Orthofix common stock suffered sha ...

NEW YORK, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of Texas on behalf of all persons or entities who purchased or otherwise acquired Orthofix Medical, Inc. ("Orthofix" or the "Company") (NASDAQ: OFIX) securities between October 11, 2022, and September 12, 2023, inclusive (the "Class Period"). The lawsuit seeks to recover damages for the Company's investors under the ...

Patients with femur and tibia abnormalities are frequently difficult to treat and have had several procedures in the past. With the revolutionary new Fitbone Transport and Lengthening System, extremely difficult conditions can be fixed without the need for numerous follow-up procedures by allowing bone to be transferred across the defect. The Fitbone TAA Intramedullary Lengthening System is intended for limb lengthening of the femur and tibia. With the combination of preoperative planning, specialist Fitbon ...

LOS ANGELES, May 16, 2024 (GLOBE NEWSWIRE) -- MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies and products in the global digital health and medical technology market, today announced that Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, has been selected as winner of the "Best Patient Experience Solution" award in the 8th annual MedTech Breakthrough Awards program. The 2024 MedTech Breakthrough Award re ...

Price Performance In the past six months, OFIX's shares have gained 41.2% compared with the industry's rise of 23.9%. The S&P 500 increased 16.2% in the same time frame. More on the News The Rodeo Telescopic Nail is a novel surgical tool designed to cure fractures or abnormalities in individuals with osteogenesis imperfecta (OI). In addition to telescoping to suit pediatric patients' natural growth, the nail implant stabilizes the patient's limb. Orthofix Medical Inc. (OFIX) recently announced the receipt o ...

Orthofix Medical Inc. (NASDAQ:OFIX) Q1 2024 Earnings Conference Call May 7, 2024 8:30 AM ET Company Participants Louisa Smith – Gilmartin Group Massimo Calafiore – President and Chief Executive Officer Julie Andrews – Chief Financial Officer Conference Call Participants Mathew Blackman – Stifel Jason Wittes – ROTH MKM Jeff Cohen – Ladenburg Thalmann Operator Thank you for standing by. My name is Jale, and I’ll be your conference operator today. At this time I’d like welcome everyone to the Orthofix Q1 2024 ...

Supplemental Financials 1Q24 Earnings () ORTHOFIX® Forward Looking Statements ©2024 Orthofix Medical Inc. All rights reserved | 1 May 7, 2024 ©2024 Orthofix Medical Inc. All rights reserved | Q1 Adjusted Gross Margin: 70.3% vs 70.7% in 1Q23 Q1 R&D: $19.5M; 10.3% of sales vs $23.3M in 1Q23; 13.3% of sales This presentation contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, relatin ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 0-19961 ORTHOFIX MEDICAL INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation ...